Pancreatic cancer: Progress made
Authors:
- Nicholas J. ZyromskiNZNicholas J. Zyromski
- Attila NakeebANAttila Nakeeb
- Keith D. LillemoeKLKeith D. Lillemoe
- 8 January 2010
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 49 (4) , 407-417
Abstract
Pancreatic cancer remains a deadly disease. Despite advances on many fronts, surgeons play a leading role in the diagnosis and management of pancreatic cancer. Preoperative staging is best provided by “pancreas-protocol” abdominal CT, although endoscopic ultrasound and diagnostic laparoscopy can add value in selected patients. Surgical resection, which remains the only curative option, is now accomplished with uniformly low perioperative mortality in high-volume centers (<3%), although complications remain frequent. Unfortunately, the long-term prognosis for pancreatic cancer remains poor with 5-year survival rates only 15–23% with median survival of 13 to 18 months. Recent data from randomized trials have supported the role for adjuvant chemotherapy and questioned the traditional role of radiation. Early diagnosis and targeted multimodality treatments would appear essential to optimizing the results of surgical therapy.Keywords
This publication has 58 references indexed in Scilit:
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Pancreatic Cancer–Associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of CancerGastroenterology, 2008
- Fatty PancreasAnnals of Surgery, 2007
- Multimodality therapy for pancreatic cancer in the U.S.Cancer, 2007
- National Failure to Operate on Early Stage Pancreatic CancerAnnals of Surgery, 2007
- Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial NeoplasiaThe American Journal of Pathology, 2007
- One Thousand Consecutive PancreaticoduodenectomiesAnnals of Surgery, 2006
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- EUS-guided celiac plexus neurolysis and celiac plexus blockGastrointestinal Endoscopy, 2003
- Chemical Splanchnicectomy in Patients with Unresectable Pancreatic Cancer A Prospective Randomized TrialAnnals of Surgery, 1993